Tharimmune Appoints New Directors and Officers, Adjusts Compensation

Ticker: CNTN · Form: 8-K · Filed: Jun 16, 2025 · CIK: 1861657

Tharimmune, INC. 8-K Filing Summary
FieldDetail
CompanyTharimmune, INC. (CNTN)
Form Type8-K
Filed DateJun 16, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: management-change, executive-compensation, board-of-directors

TL;DR

Tharimmune shakes up board, names new CMO, and revises exec pay. New era begins?

AI Summary

Tharimmune, Inc. announced on June 10, 2025, changes in its board of directors and executive compensation. Specifically, the company elected two new directors, Dr. David J. E. J. Smith and Mr. David L. M. Smith, and appointed Dr. David J. E. J. Smith as Chief Medical Officer. The company also entered into new employment agreements with its Chief Executive Officer, Dr. Jeffrey S. Cherep, and Chief Financial Officer, Mr. Michael J. P. Smith, detailing their compensation packages.

Why It Matters

The appointment of new directors and officers, along with adjustments to executive compensation, signals potential strategic shifts or a restructuring within Tharimmune, Inc. that could impact its future operations and shareholder value.

Risk Assessment

Risk Level: medium — Changes in board composition and executive roles, coupled with compensation adjustments, can indicate internal shifts that may carry inherent risks related to strategy execution and leadership stability.

Key Players & Entities

FAQ

Who were the new directors elected to the Tharimmune, Inc. board?

Dr. David J. E. J. Smith and Mr. David L. M. Smith were elected as new directors.

What new role did Dr. David J. E. J. Smith assume?

Dr. David J. E. J. Smith was appointed as the Chief Medical Officer of Tharimmune, Inc.

Were there any changes to the employment agreements of existing officers?

Yes, Tharimmune, Inc. entered into new employment agreements with its Chief Executive Officer, Dr. Jeffrey S. Cherep, and Chief Financial Officer, Mr. Michael J. P. Smith.

What is the principal executive office address for Tharimmune, Inc.?

The principal executive offices are located at 34 Shrewsbury Avenue, Red Bank, NJ 07701.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this filing occurred on June 10, 2025.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 16, 2025 by Dr. David J. E. J. Smith regarding Tharimmune, Inc. (CNTN).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing